{"title":"关于全球和欧洲艾滋病毒/艾滋病和结核分枝杆菌/结核病供资的补充资料","authors":"C. Giehl","doi":"10.2174/1874279301005010089","DOIUrl":null,"url":null,"abstract":"The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. In the context of the their TB/HIV Advocacy Project supported by the Bill & Melinda Gates Foundation, TAG has been compiling the “Treatment Action Group’s report on funding trends for tuberculosis (TB) research and development (R&D)”, monitoring global spending for TB R&D from the baseline year 2005 to date [1].","PeriodicalId":88330,"journal":{"name":"The open infectious diseases journal","volume":"5 1","pages":"89-90"},"PeriodicalIF":0.0000,"publicationDate":"2011-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Supplementary Information on Global and European Funding on HIV/AIDS and M. tuberculosis/TB\",\"authors\":\"C. Giehl\",\"doi\":\"10.2174/1874279301005010089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. In the context of the their TB/HIV Advocacy Project supported by the Bill & Melinda Gates Foundation, TAG has been compiling the “Treatment Action Group’s report on funding trends for tuberculosis (TB) research and development (R&D)”, monitoring global spending for TB R&D from the baseline year 2005 to date [1].\",\"PeriodicalId\":88330,\"journal\":{\"name\":\"The open infectious diseases journal\",\"volume\":\"5 1\",\"pages\":\"89-90\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The open infectious diseases journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874279301005010089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open infectious diseases journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874279301005010089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Supplementary Information on Global and European Funding on HIV/AIDS and M. tuberculosis/TB
The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. In the context of the their TB/HIV Advocacy Project supported by the Bill & Melinda Gates Foundation, TAG has been compiling the “Treatment Action Group’s report on funding trends for tuberculosis (TB) research and development (R&D)”, monitoring global spending for TB R&D from the baseline year 2005 to date [1].